Literature DB >> 15539713

Normal pulmonary capillary blood volume in patients with chronic infiltrative lung disease and high pulmonary artery pressure.

Marcel Bonay1, Catherine Bancal, Dominique de Zuttere, Florence Arnoult, Georges Saumon, Françoise Camus.   

Abstract

STUDY
OBJECTIVES: Pulmonary capillary blood volume (Qc), a component of diffusing capacity of the lung for carbon monoxide (Dlco), is increased in postcapillary pulmonary hypertension due to valve disease, but is decreased in primitive and thromboembolic pulmonary hypertension. This study was performed to evaluate which way pulmonary Qc is affected in patients with chronic infiltrative lung disease according to the value of systolic pulmonary artery pressure (SPAP). PATIENTS AND METHODS: Twenty-four patients who were nonsmokers and had chronic infiltrative lung disease secondary to connective tissue disease (12 patients), asbestosis (1 patient), sarcoidosis (5 patients), or of unknown origin (6 patients), and 8 control subjects underwent pulmonary function tests and Doppler echocardiography. MEASUREMENTS AND
RESULTS: Total lung capacity, alveolar-arterial oxygen pressure difference, Dlco, and conductance of the alveolar-capillary membrane (Dm) did not differ between patients with low SPAP (LPAP) [ie, < 30 mm Hg] or high SPAP (HPAP). Patients with LPAP, but not HPAP, experienced significant decreases in pulmonary Qc, whatever the cause of the disease. There was a strong positive correlation between SPAP and Qc scaled by Dm to account for infiltrative disease severity (r = 0.68; p < 0.001).
CONCLUSIONS: We thus conclude that pulmonary Qc is not decreased as expected in patients with chronic infiltrative lung disease and high pulmonary artery pressure. A high Qc/Dm ratio should encourage the physician to look for HPAP compatible with pulmonary hypertension, whatever the etiology of lung infiltrative disease.

Entities:  

Mesh:

Year:  2004        PMID: 15539713     DOI: 10.1378/chest.126.5.1460

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  5 in total

1.  Prediction of pulmonary hypertension in idiopathic pulmonary fibrosis.

Authors:  David A Zisman; David J Ross; John A Belperio; Rajan Saggar; Joseph P Lynch; Abbas Ardehali; Arun S Karlamangla
Journal:  Respir Med       Date:  2007-07-02       Impact factor: 3.415

Review 2.  CO and NO pulmonary diffusing capacity during pregnancy: Safety and diagnostic potential.

Authors:  Gerald S Zavorsky; Arlin B Blood; Gordon G Power; Lawrence D Longo; Raul Artal; Emanuel J Vlastos
Journal:  Respir Physiol Neurobiol       Date:  2010-02-10       Impact factor: 1.931

Review 3.  Management of Pulmonary Hypertension in Patients with Chronic Lung Disease.

Authors:  Joan Albert Barberà; Isabel Blanco
Journal:  Curr Hypertens Rep       Date:  2015-08       Impact factor: 5.369

4.  Lung injury in vivax malaria: pathophysiological evidence for pulmonary vascular sequestration and posttreatment alveolar-capillary inflammation.

Authors:  Nicholas M Anstey; Tjandra Handojo; Michael C F Pain; Enny Kenangalem; Emiliana Tjitra; Ric N Price; Graeme P Maguire
Journal:  J Infect Dis       Date:  2007-01-04       Impact factor: 5.226

5.  Membrane diffusion- and capillary blood volume measurements are not useful as screening tools for pulmonary arterial hypertension in systemic sclerosis: a case control study.

Authors:  Maria J Overbeek; Herman Groepenhoff; Alexandre E Voskuyl; Egbert F Smit; Jochem W L Peeters; Anton Vonk-Noordegraaf; Marieke D Spreeuwenberg; Ben C Dijkmans; Anco Boonstra
Journal:  Respir Res       Date:  2008-10-01
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.